HiberCell

About:

HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutic agents targeting adaptive stress.

Website: https://www.hibercell.com

Top Investors: Hercules Capital, Bristol-Myers Squibb, ARCH Venture Partners, Hillhouse Investment, Monashee Investment Management

Description:

HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis. The company was founded in 2019 and is based in New York.

Total Funding Amount:

$158M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2019-01-01

Contact Email:

contact(AT)hibercell.com

Founders:

Alan Rigby, Ari Nowacek, Julio Aguirre-Ghiso

Number of Employees:

51-100

Last Funding Date:

2021-05-19

IPO Status:

Private

Industries: